Literature DB >> 10775585

The carboxyl terminus of v-Abl protein can augment SH2 domain function.

D Warren1, A J Heilpern, K Berg, N Rosenberg.   

Abstract

Abelson murine leukemia virus (Ab-MLV) transforms NIH 3T3 and pre-B cells via expression of the v-Abl tyrosine kinase. Although the enzymatic activity of this molecule is absolutely required for transformation, other regions of the protein are also important for this response. Among these are the SH2 domain, involved in phosphotyrosine-dependent protein-protein interactions, and the long carboxyl terminus, which plays an important role in transformation of hematopoietic cells. Important signals are sent from each of these regions, and transformation is most likely orchestrated by the concerted action of these different parts of the protein. To explore this idea, we compared the ability of the v-Src SH2 domain to substitute for that of v-Abl in the full-length P120 v-Abl protein and in P70 v-Abl, a protein that lacks the carboxyl terminus characteristic of Abl family members. Ab-MLV strains expressing P70/S2 failed to transform NIH 3T3 cells and demonstrated a greatly reduced capacity to mediate signaling events associated with the Ras-dependent mitogen-activated protein (MAP) kinase pathway. In contrast, Ab-MLV strains expressing P120/S2 were indistinguishable from P120 with respect to these features. Analyses of additional mutants demonstrated that the last 162 amino acids of the carboxyl terminus were sufficient to restore transformation. These data demonstrate that an SH2 domain with v-Abl substrate specificity is required for NIH 3T3 transformation in the absence of the carboxyl terminus and suggest that cooperativity between the extreme carboxyl terminus and the SH2 domain facilitates the transmission of transforming signals via the MAP kinase pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775585      PMCID: PMC111963          DOI: 10.1128/jvi.74.10.4495-4504.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras.

Authors:  J de Rooij; J L Bos
Journal:  Oncogene       Date:  1997-02-06       Impact factor: 9.867

Review 2.  The viral and cellular forms of the Abelson (abl) oncogene.

Authors:  N Rosenberg; O N Witte
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

3.  The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals.

Authors:  S Gupta; H Yan; L H Wong; S Ralph; J Krolewski; C Schindler
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

4.  Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens.

Authors:  B Chesebro; K Wehrly; M Cloyd; W Britt; J Portis; J Collins; J Nishio
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

5.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

6.  The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter.

Authors:  B J Wagner; T E Hayes; C J Hoban; B H Cochran
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

7.  SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.

Authors:  A M Pendergast; M L Gishizky; M H Havlik; O N Witte
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

8.  Jak-STAT signaling induced by the v-abl oncogene.

Authors:  N N Danial; A Pernis; P B Rothman
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

9.  Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.

Authors:  L Puil; J Liu; G Gish; G Mbamalu; D Bowtell; P G Pelicci; R Arlinghaus; T Pawson
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

10.  The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity.

Authors:  R A Van Etten; P K Jackson; D Baltimore; M C Sanders; P T Matsudaira; P A Janmey
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

View more
  7 in total

1.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

2.  Disruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis.

Authors:  Linda B Baughn; Naomi Rosenberg
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus.

Authors:  David Warren; Deborah S Griffin; Celine Mainville; Naomi Rosenberg
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

5.  Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.

Authors:  C A Mainville; K Parmar; I Unnikrishnan; L Gong; G D Raffel; N Rosenberg
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Absence of p53 complements defects in Abelson murine leukemia virus signaling.

Authors:  Indira Unnikrishnan; Naomi Rosenberg
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  Genome-wide prediction of SH2 domain targets using structural information and the FoldX algorithm.

Authors:  Ignacio E Sánchez; Pedro Beltrao; Francois Stricher; Joost Schymkowitz; Jesper Ferkinghoff-Borg; Frederic Rousseau; Luis Serrano
Journal:  PLoS Comput Biol       Date:  2008-04-04       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.